# Personalized Medicine & Disease Progression Monitoring

> How a longitudinal biomarker platform turned scattered lab values into a per-patient progression signal clinicians could act on.

By Good AI Research · Published 2026-11-11 · Source: https://thegoodai.ai/insights/personalized-medicine

## Key takeaways

- Longitudinal, not snapshot: models see the whole trajectory
- Every output is traceable to the raw values behind it
- Decision support with a clinician in the loop, always

## The problem

Progression in chronic and oncologic disease is judged at visit intervals, from whichever values happen to be in front of the clinician. Patterns that span months, like a biomarker drifting or a response plateauing, are easy to miss until the next imaging or the next event.

## What we built

A biomarker platform that ingests longitudinal lab, imaging-derived and clinical variables per patient, harmonises units and reference ranges, and fits progression models against validated clinical cohorts. Every model output is shown next to the raw values it was derived from, so a clinician can disagree with the trend in seconds.

## How it is governed

The platform recommends; it never decides. Outputs are decision support, reviewed by a qualified clinician, with full audit trails and role-based access aligned to HIPAA and GDPR. Model versions are pinned and every recommendation is replayable.

## What changed

Earlier, more consistent identification of patients whose trajectory was changing, and a shared, explainable view of why. The same pipeline now underpins the biomarker work on the BioLens diagnostics platform.